

A spokesperson from Therapeutic Goods Administration:

- The Therapeutic Goods Administration (TGA) is aware of, and concerned about, the increasing advertising of unapproved peptides, including where these are promoted under the guise of competitive events, and will continue to monitor these activities and will action enforcement as appropriate.
- Sports Integrity Australia issued a health warning, available at [Enhanced Games | Statement by Sport Integrity Australia](#).
- We work collaboratively with international and domestic partners, including law enforcement and regulatory agencies, to detect unlawful import, export, supply, manufacture and advertising of therapeutic goods in Australia.
- We actively monitor online advertising and work with digital platforms to remove unlawful content within our jurisdiction.
- Peptide products intercepted at the border may be seized and destroyed if they cannot be lawfully imported under the Personal Importation Scheme, including where they are unclearly labelled or labelled to avoid regulatory scrutiny.
- The recent joint operation with the ABF and Victoria Police [media release](#) demonstrates the seriousness with which the TGA views unlawful activities involving therapeutic goods and the regulatory action it is prepared to take.
- The TGA strongly recommends that consumers exercise caution and understand the risks associated with [buying medicines and medical devices online](#), especially unapproved medicines and where prescription-only medicines are offered or supplied without a valid prescription or consultation with a qualified health professional.
 - Such products may contain undisclosed (hidden) or harmful ingredients, incorrect dosages, or undeclared prescription medicines, and may pose a serious risk to your health.
- Between 1 July 2025 and 31 December 2025, [over 13,000 reports of alleged unlawful](#) therapeutic good import, export, manufacture, supply or advertising were received by the TGA. Some of these reports will relate to peptides.
- The TGA has published recent [safety alerts](#) regarding the importation, supply and use of unapproved peptide products. These alerts highlight potential risks

associated with products that have not been evaluated for safety, quality or efficacy by the TGA.

- The TGA does not comment on individual matters beyond the published [safety alerts](#) and compliance [outcomes](#).

- GHK-Cu is not specifically scheduled in the Poisons Standard. Any therapeutic product must be included in the Australian Register of Therapeutic Goods (ARTG) before it can be marketed for human use.

- GHK-Cu has not been evaluated by the TGA for its quality, safety and efficacy for use in humans and is not registered on the ARTG.